Medicago to present at the 3rd International Conference on Influenza Vaccines of the World



    QUEBEC CITY, April 29 /CNW/ - Medicago Inc. (TSX-V: MDG), a biotechnology
company focused on developing highly effective and affordable vaccines based
on proprietary manufacturing technologies and Virus-Like Particles (VLPs),
today announced that that it will be presenting at The Third International
Conference on Influenza Vaccines for the World from April 27-30, 2009 at the
Palais des Festivals et des Congrès, Cannes Cedex, France. Ms. Nathalie
Landry, VP Product Development, will present Medicago's unique solution for
the rapid and cost effective production of pandemic flu vaccines in a session
entitled "Adjuvants, VLPs and Delivery" being held on Thursday April 30th at
10:05 pm.
    Ms. Landry's presentation entitled "Innovative H5N1 Virus-Like Particles:
a unique combination of product and manufacturing solution" will focus on
Medicago's recent preclinical results with its H5N1 pandemic VLP vaccine,
which has shown to be immunogenic at doses as low as 5 micrograms and provides
100% cross-protection to different strains of the H5N1 virus. In light of the
recent Swine Flu outbreak, the presentation will also discuss Medicago's
ability to rapidly respond to a pandemic with its plant-based manufacturing
technology, a system that combined with the Company's VLP technology, could
deliver a vaccine just one month after the identification of the genetic
sequence from an emerging pandemic strain.

    About Medicago

    Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at www.medicago.com.

    Forward Looking Statements

    This press release contains forward-looking statements which reflect
Medicago's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. Medicago disclaims any obligation to
update these forward-looking statements.

    
    The TSX Venture Exchange assumes no responsibility for the content or
    accuracy of this press release
    





For further information:

For further information: Medicago, Inc., Andy Sheldon, President and
CEO, (418) 658-9393; Medicago Inc., Arianna Vanin, Director, Investor
Relations, (514) 796-3993

Organization Profile

Medicago Inc.

More on this organization

FLU VIRUS UPDATE

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890